A neuropsychiatric perspective of phenylketonuria II: Needs assessment for a psychiatric presence

Psychosomatics

Volumn 53, Issue 6, 2012, Pages 541-549

  Angelino, Andrew F ^a   Bone, Ashley ^a   Kuehl, Angela K ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Symbiotix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBIVALENCE; APATHY; ARTICLE; COGNITIVE DEFECT; FOLLOW UP; FRUSTRATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; NEUROPSYCHIATRY; PATIENT REFERRAL; PHENYLKETONURIA; SCREENING; UNITED STATES;

ADULT; AMBULATORY CARE FACILITIES; CHILD; COGNITION DISORDERS; HEALTH CARE SURVEYS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INTERNET; MASS SCREENING; MENTAL HEALTH SERVICES; PATIENT CARE TEAM; PATIENT COMPLIANCE; PHENYLALANINE; PHENYLKETONURIAS; REFERRAL AND CONSULTATION; UNITED STATES;

EID: 84875803999     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2012.04.011     Document Type: Article

References (37)

1. Hoeks M.P., den H.M., Janssen M.C. Adult issues in phenylketonuria. Neth J Med 2009, 67(1):2-7.
2. Phenylketonuria: screening and management, October 16-18, 2000. Pediatrics 2001, 108:972-982. National Institutes of Health Consensus Developmental Panel, National Institutes of Health Consensus Developmental Conference Statement.
3. Christ S.E., Huijbregts S.C.J., de Sonneville L.M.J., White D.A. Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol Genet Metab 2010, 99:S22-S32.
4. Northam E.A. Neuropsychological and psychosocial correlates of endocrine and metabolic disorders-a review. J Pediatr Endocrinol Metab 2004, 17:5-15.
5. DeRoche K., Welsh M. Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function. Dev Neuropsychol 2008, 33:474-504.
6. Brumm V.L., Bilder D., Waisbren S.E. Psychiatric symptoms and disorders in PKU: children and adults. Mol Genet Metab 2010, 99(Suppl 1):S59-S63.
7. Waisbren S., White D.A. Screening for cognitive and social-emotional problems in individuals with PKU: tools for use in the metabolic clinic. Mol Genet Metab 2010, 99(Suppl 1):S96-S99.
8. Christ S.E., Moffitt A.J., Peck D. Disruption of prefrontal function and connectivity in individuals with phenylketonuria. Mol Genet Metab 2010, 99(Suppl 1):S33-S40.
9. Macdonald A., Ahring K., Dokoupil K., Gokmen-Ozel H., Lammardo A.M., Motzfeldt K., et al. Adjusting diet with sapropterin in phenylketonuria: what factors should be considered?. Br J Nutr 2011, 5:1-8.
10. Koch R., Trefz F., Waisbren S. Psychosocial issues and outcomes in maternal PKU. Mol Genet Metab 2010, 99(Suppl 1):S68-S74.
11. Hegge K.A., Horning K.K., Peitz G.J., Hegge K. Sapropterin: a new therapeutic agent for phenylketonuria. Ann Pharmacother 2009, 43(9):1466-1473.
12. Azadi B., Seddigh A., Tehrani-Doost M., Alaghband-Rad J., Ashrafi M.R. Executive dysfunction in treated phenylketonuric patients. Eur Child Adolesc Psychiatry 2009, 18(6):360-368.
13. Albrecht J., Garbade S.F., Burgard P. Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis. Neurosci Biobehav Rev 2009, 33(3):414-421.
14. Koch R., Burton B., Hoganson G., Peterson R., Rhead W., Rouse B., et al. Phenylketonuria in adulthood: a collaborative study. J Inherit Metab Dis 2002, 25(5):333-346.
15. Surtees R., Blau N. The neurochemistry of phenylketonuria. Eur J Pediatr 2000, 159:S109-S113.
16. Camfield C.S., Joseph M., Hurley T., Campbell K., Sanderson S., Camfield P.R. Optimal management of phenylketonuria: a centralized expert team is more successful than a decentralized model of care. J Pediatr 2004, 145(1):53-57.
17. Waisbren S., White D.A. Screening for cognitive and social-emotional problems in individuals with PKU: tools for use in the metabolic clinic. Mol Genet Metab 2010, 99(Suppl 1):S96-S99.
18. Leviton L, Vespa H, Burton B: Mental health screening in the phenylketonuria (PKU) clinic. Poster session. Proceedings of the American College of Medical Genetics Annual Meeting, 2011 March 16-20; Vancouver, Canada.
19. Stilley C.S., Bender C.M., Dunbar-Jacob J., Sereika S., Ryan C.M. The impact of cognitive function on medication management: three studies. Health Psychol 2010, 29(1):50-55.
20. May H.T., Sheng X., Catinella A.P., Horne B.D., Carlquist J.F., Joy E. Antilipidemic adherence post-coronary artery disease diagnosis among those with and without an ICD-9 diagnosis of depression. J Psychosom Res 2010, 69(2):169-174.
21. Krousel-Wood M.A., Frohlich E.D. Hypertension and depression: coexisting barriers to medication adherence. J Clin Hypertens 2010, 12(7):481-486.
22. Krousel-Wood M.K., Islam T., Muntner P., Holt E., Joyce C., Morisky D.E., et al. Association of depression with antihypertensive medication adherence in older adults: cross-sectional and longitudinal findings from CoSMO. Am Behav Med 2010, 40(3):248-257.
23. Hayes T.L., Larimer N., Adami A., Kaye J.A. Medication adherence in healthy elders: small cognitive changes make a big difference. J Aging Health 2009, 21(4):567-580.
24. De Jong M.J., Chung M.L., Wu J.-R., Riegel B., Rayens M.K., Moser D.K. Linkages between anxiety and outcomes in heart failure. Heart Lung 2011, 40(5):393-404.
25. Welsh M.C., Pennington B.F., Ozonoff S., Rouse B., McCabe E.R. Neuropsychology of early-treated phenylketonuria: specific executive function deficits. Child Dev 1990, 61(6):1697-1713.
26. White D.A., Nortz M.J., Mandernach T., Huntington K., Steiner R.D. Deficits in memory strategy use related to prefrontal dysfunction during early development: evidence from children with phenylketonuria. Neuropsychology 2001, 15(2):221-229.
27. Channon S., German E., Cassina C., Lee P. Executive functioning, memory, and learning in phenylketonuria. Neuropsychology 2004, 18(4):613-620.
28. White D.A., Nortz M.J., Mandernach T., Huntington K., Steiner R.D. Age-related working memory impairments in children with prefrontal dysfunction associated with phenylketonuria. J Int Neuropsychol Soc 2002, 8(1):1-11.
29. Christ S.E., Steiner R.D., Grange D.K., Abrams R.A., White D.A. Inhibitory control in children with phenylketonuria. Dev Neuropsychol 2006, 30(3):845-864.
30. Huijbregts S., de Sonneville, Licht R., Sergeant J., van Spronsen F. Inhibition of prepotent responding and attentional flexibility in treated phenylketonuria. Dev Neuropsychol 2002, 22(2):481-499.
31. Brumm V.L., Azen C., Moats R.A., Stern A.M., Broomand C., Nelson M.D., et al. Neuropsychological outcome of subjects participating in the PKU Adult Collaborative Study: a preliminary review. J Inherit Metab Dis 2004, 27(5):549-566.
32. Waisbren S.E., Noel K., Fahrbach K., Cella C., Frame D., Dorenbaum A., et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab 2007, 92(1/2):63-70.
33. Gassió R., Vilaseca M.A., Lambruschini N., Boix C., Fusté M.E., Campistol J. Cognitive functions in patients with phenylketonuria in long-term treatment with tetrahydrobiopterin. Mol Genet Metab 2010, 99:S75-S78.
34. ten Hoedt A.E., de Sonneville L.M.J., Francois B., ter Horst N.M., Janssen M.C., Rubio-Gozalbo M.E., et al. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomized, double-blind, placebo-controlled, crossover trial. J Inherit Metab Dis 2011, 34:165-171.
35. Levy H.L., Milanowski A., Chakrapani A., Cleary M., Lee P., Trefz F.K., et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, GR-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomized placebo-controlled study. Lancet 2007, 370(9586):504-510. Sapropterin Research Group.
36. Anastasoaie V., Kurzius L., Forbes P., Waisbren S. Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Mol Genet Metab 2008, 95:17-20.
37. Safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in phenylketonuria (PKU) patients. ClinicalTrials.gov [Internet] 2000, BioMarin Pharmaceutical Inc., National Library of Medicine (US), Bethesda (MD), NLM Identifier: NCT011114737. Accessed February 27, 2002. http://clinicaltrials.gov/ct2/show/NCT01114737%20NLM%20Identifier:%20NCT011114737.